The development and validation of a microneutralization assay for the detection and quantification of anti-yellow fever virus antibodies in human serum
With increased globalization and shifting climate patterns, yellow fever (YF) is re-emerging as a global threat. At present, vaccination remains the most effective prevention strategy. This study describes the development and validation of a new YF microneutralization (MN) assay for the detection and quantification of YF virus-neutralizing antibodies in human serum that offers increased throughput compared with the current standard assay. Overall, the YF MN assay demonstrated acceptable intra-assay precision (repeatability), intermediate precision, dilutional accuracy, linearity, and specificity and is suitable for the detection of YF virus-neutralizing antibodies. Further, the Center for Biologics Evaluation and Research (CBER) supports the use of the YF MN assay in the licensure of candidate YF vaccines.
Authors
- Katherine Fries
- James W. Huleatt
- Robert J. Goldberg (ORCID: https://orcid.org/0000-0001-7705-7740)
- Louis Devlin
- Lingyi Zheng (ORCID: https://orcid.org/0000-0002-3446-3447)
- Ping Luo (ORCID: https://orcid.org/0000-0002-8167-1900)
- R W Baldwin
- Ivan Ordonez
Institutions
- Sanofi (France) (FR)
- Sanofi (United States) (US)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1128/spectrum.03348-24
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 0.00